2:25 AM
 | 
Oct 23, 2017
 |  BC Extra  |  Financial News

ADC Therapeutics raises $200M

Antibody-drug conjugate company ADC Therapeutics S.A. (Épalinges, Switzerland) raised $200 million in a private placement from Auven Therapeutics Management, Redmile, the Wild Family Office and AstraZeneca plc (LSE:AZN; NYSE:AZN).

Next year, ADC Therapeutics plans to start registrational trials of lead candidates ADCT-301 (HuMax-TAC-ADC) and

Read the full 222 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >